NCT05126342 2025-04-06
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
AGO Research GmbH
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT04510584 2023-06-06
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
University Health Network, Toronto
Phase 2 Withdrawn
NCT02487849 2020-03-04
HIPEC
Krankenhaus Barmherzige Schwestern Linz
Phase 2 Withdrawn
NCT01766622 2019-12-04
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02948101 2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00005645 2018-09-18
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
Sanofi
Phase 2 Withdrawn
NCT00634894 2016-04-20
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01131039 2013-12-20
Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Emory University
Phase 2 Withdrawn
NCT00369954 2013-06-10
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
GOG Foundation
Phase 2 Withdrawn
NCT01661868 2012-08-21
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Withdrawn